Attovia Therapeutics raises $289.0M IPO (United States, Aug 2026)

Immunotherapy Startup Attovia Lists on Nasdaq: IPO Raises $289 Million, First-Day Market Cap Tops $900 Million - finance.biggo.com

Attovia Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for immune-mediated diseases. The company holds an exclusive global license to the ATTOBODY biologics platform, which enables the rapid generation of diverse candidate molecules. Attovia has already nominated three product candidates and aims to advance their clinical development with proceeds from their recent IPO.

Immunotherapy Startup Attovia Lists on Nasdaq: IPO Raises $289 Million, First-Day Market Cap Tops $900 Million  finance.biggo.com